Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma

被引:9
作者
Ito, Keiichi [1 ]
Yoshii, Hidehiko [1 ]
Asano, Takako [1 ]
Horiguchi, Akio [1 ]
Sumitomo, Makoto [1 ]
Hayakawa, Masamchi [1 ]
Asano, Tomohiko [1 ]
机构
[1] Natl Def Med Coll, Dept Urol, Tokorozawa, Saitama 3598513, Japan
关键词
renal cell carcinoma; erythropoietin; erythropoietin receptor; prognosis; microvascular invasion; DEPENDENT PATHWAY; CANCER; COEXPRESSION;
D O I
10.3892/etm.2012.513
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Erythropoietin (EPO) expression and EPO receptor (EpoR) expression have been demonstrated in various malignant tumors. EPO-EpoR signaling can activate several downstream signal transduction pathways that enhance tumor aggressiveness. The present study was undertaken to evaluate the impact of overexpression of EpoR and elevated serum EPO (sEPO) levels on the clinicopathological features and prognosis of patients with renal cell carcinoma (RCC). EpoR expression was evaluated immunohistochemically in 56 patients. Tumors with a staining intensity greater than that of surrounding proximal tubules were defined as tumors with high EpoR expression. The association between EpoR expression levels and various clinicopathological factors was analyzed. sEPO levels were determined in 138 patients and its correlation to clinicopathological factors was also analyzed, and EpoR expression was determined in surgical specimens removed from 47 of those 138 patients. Patients with high EpoR expression and patients with sEPO elevation had clinicopathological features less favorable than those of other patients. Tumors demonstrating high EpoR expression had a significantly higher number of Ki-67-positive cells compared to those with low EpoR expression. Tumor assemblies in microvessels demonstrated high EpoR expression. Patients whose tumors demonstrated high EpoR expression and those with sEPO elevation had a significantly lower survival rate compared to other patients, and patients with both high EpoR expression and sEPO elevation had an extremely poor prognosis. Microvascular invasion was an independent factor associated with sEPO elevation, suggesting that EPO-EpoR signaling might be important in RCC metastasis. EPO-EpoR signaling may be involved in tumor growth and progression in RCC and the combination of EpoR expression and sEPO levels may effectively predict clinical outcome.
引用
收藏
页码:937 / 944
页数:8
相关论文
共 20 条
[11]  
LJUNGBERG B, 1992, EUR UROL, V21, P160
[12]   Prognostic significance of erythropoietin expression in human renal cell carcinoma [J].
Michael, Agniezka ;
Politi, Ekaterini ;
Havranek, Erik ;
Corbishley, Catherine ;
Karapanagiotou, Lena ;
Anderson, Chris ;
Relph, Kate ;
Syrigos, Konstantinos N. ;
Pandha, Hardev .
BJU INTERNATIONAL, 2007, 100 (02) :291-294
[13]  
Miyajima A, 2002, CANCER RES, V62, P4176
[14]   Expression of Erythropoietin and Its Receptor in Human Renal Cell Carcinoma [J].
Papworth, Karin ;
Bergh, Anders ;
Grankvist, Kjell ;
Ljungberg, Borje ;
Rasmuson, Torgny .
TUMOR BIOLOGY, 2009, 30 (02) :86-92
[15]   Erythropoietin as an angiogenic factor in gastric carcinoma [J].
Ribatti, D ;
Marzullo, A ;
Nico, B ;
Crivellato, E ;
Ria, R ;
Vacca, A .
HISTOPATHOLOGY, 2003, 42 (03) :246-250
[16]   Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer [J].
Saintigny, Pierre ;
Besse, Benjamin ;
Callard, Patrice ;
Vergnaud, Anne-Claire ;
Czernichow, Sebastien ;
Colombat, Magali ;
Girard, Philippe ;
Validire, Pierre ;
Breau, Jean-Luc ;
Bernaudin, Jean-Francois ;
Soria, Jean-Charles .
CLINICAL CANCER RESEARCH, 2007, 13 (16) :4825-4831
[17]   Erythropoietin and its lost receptor [J].
Sturiale, Alessio ;
Campo, Susanna ;
Crasci, Eleonora ;
Coppolino, Giuseppe ;
Bolignano, Davide ;
Grasso, Giovanni ;
Buemi, Michele .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (05) :1484-1485
[18]   Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells [J].
Tilbrook, PA ;
Colley, SM ;
McCarthy, DJ ;
Marais, R ;
Klinken, SP .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 396 (01) :128-132
[19]   Erythropoietin protects against ischaemic acute renal injury [J].
Vesey, DA ;
Cheung, C ;
Pat, B ;
Endre, Z ;
Gobé, G ;
Johnson, DW .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (02) :348-355
[20]   Erythropoietin stimulates proliferation of human renal carcinoma cells [J].
Westenfelder, C ;
Baranowski, RL .
KIDNEY INTERNATIONAL, 2000, 58 (02) :647-657